Nice article! Extracts from the article relating to Anteris below:
”Fixing broken hearts Chris Kallos I’m quite excited about Anteris Technologies (ASX: AVR), which runs a proprietary tissue engineering business. Having already sold validated heart-repair tissue to a French company, it is now working on manufacturing a heart valve and is currently running open-heart surgery trials in Belgium. If successful, Anteris could be worth between US$200 million and US$400 million a year from now, from its current market cap of around $22 million. Both the heart valve and the tissue are proprietary – and that’s huge. But the big story is that the company aims to enter the transcatheter aortic valve replacement therapy (TAVR) market. Open-heart surgery for elderly people has always been very risky, so surgeons now often introduce catheters via other parts of the body. Anteris is currently making sure its proprietary valve works in normal patients, and will then put a submission to the US Food and Drug Administration sometime in 2021.”
Ann: Funding Package, page-90
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 830 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |